Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.50 |
| ▸ | LPL | P06858 | 7/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29631781 | 0.92 | LIPG (0.60) | LIPGLPLHSD17B1HSD17B2APP | |
| SCHEMBL15481254 | 0.92 | LIPG (0.60) | LIPGLPLHSD17B1HSD17B2APP | |
| SCHEMBL20983994 | 0.81 | LIPG (0.63) | LIPGLPLHSD17B1HSD17B2APP | |
| SCHEMBL12700861 | 0.81 | LIPG (0.62) | LIPGLPLHSD17B1HSD17B2SNCA | |
| SCHEMBL21541874 | 0.81 | LIPG (0.55) | LIPGLPLHSD17B1HSD17B2APP | |
| SCHEMBL20984001 | 0.81 | LIPG (0.61) | LIPGLPLAPPCA1CA2 | |
| SCHEMBL757554 | 0.78 | PDGFRB (0.46) | LIPGLPLHSD17B1HSD17B2APP | |
| SCHEMBL806784 | 0.78 | LIPG (0.60) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL18015333 | 0.77 | KDM1A (0.48) | LIPGLPLSNCAPDGFRBKDR | |
| SCHEMBL2496185 | 0.77 | RAB9A (0.53) | APPSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200227650-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | DOOSAN CORPORATION (KR) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200227650-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | OR10J3, ORAI2, OR51E2 | LIPG 1355/4885LPL 745/4885HSD17B1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.